Gout Author: Grace P. Teal, MD; Howard A. Fuchs, MD
Editorial changes - 2009-09-02
Author information and module status
Prevention
Screening
Diagnosis
Consultation for Diagnosis
Hospitalization
Non-drug Therapy
Drug Therapy
Patient Education
Consultation for Management
Follow-up
Tables
Figures
References
Glossary
What's New
Patient Information
Additional Resources
Tools
References
1. 1Mahmoud HH, Leverger G, Patte C, Harvey E, Lascombes F. Advances in the management of malignancy-associated hyperuricaemia. Br J Cancer. 1998;77 Suppl 4:18-20. (PMID: 9647616)
2. 2Kjellstrand CM, Cambell DC 2nd, von Hartitzsch B, Buselmeier TJ. Hyperuricemic acute renal failure. Arch Intern Med. 1974;133:349-59. (PMID: 4283735)
3. 3Coiffier B, Altman A, Pui CH, Younes A, Cairo MS. Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin Oncol. 2008;26:2767-78. (PMID: 18509186)
4. 1Hall AP, Barry PE, Dawber TR, McNamara PM. Epidemiology of gout and hyperuricemia. A long-term population study. Am J Med. 1967;42:27-37. (PMID: 6016478)
5. 2Campion EW, Glynn RJ, DeLabry LO. Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study. Am J Med. 1987;82:421-6. (PMID: 3826098)
6. 2Kramer HM, Curhan G. The association between gout and nephrolithiasis: the National Health and Nutrition Examination Survey III, 1988-1994. Am J Kidney Dis. 2002;40:37-42. (PMID: 12087559)
7. 2Wallace KL, Riedel AA, Joseph-Ridge N, Wortmann R. Increasing prevalence of gout and hyperuricemia over 10 years among older adults in a managed care population. J Rheumatol. 2004;31:1582-7. (PMID: 15290739)
8. 2Chen SY, Chen CL, Shen ML, Kamatani N. Clinical features of familial gout and effects of probable genetic association between gout and its related disorders. Metabolism. 2001;50:1203-7. (PMID: 11586494)
9. 3Hande KR, Noone RM, Stone WJ. Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med. 1984;76:47-56. (PMID: 6691361)
10. 3Singer JZ, Wallace SL. The allopurinol hypersensitivity syndrome. Unnecessary morbidity and mortality. Arthritis Rheum. 1986;29:82-7. (PMID: 3947418)
11. 2Niskanen LK, Laaksonen DE, Nyyssonen K, Alfthan G, Lakka HM, Lakka TA, et al. Uric acid level as a risk factor for cardiovascular and all-cause mortality in middle-aged men: a prospective cohort study. Arch Intern Med. 2004;164:1546-51. (PMID: 15277287)
12. 3Wallace SL, Robinson H, Masi AT, Decker JL, McCarty DJ, Yü TF. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum. 1977;20:895-900. (PMID: 856219)
13. 3Harris MD, Siegel LB, Alloway JA. Gout and hyperuricemia. Am Fam Physician. 1999;59:925-34. (PMID: 10068714)
14. 3Grahame R, Mitchell AB, Scott JT. Chronic post-rheumatic fever (Jaccoud's) arthropathy. Ann Rheum Dis. 1970;29:622-5. (PMID: 5496065)
15. 3Puig JG, Michan AD, Jimenez ML, Perez de Ayala C, Mateos FA, Capitan CF, et al. Female gout. Clinical spectrum and uric acid metabolism. Arch Intern Med. 1991;151:726-32. (PMID: 2012455)
16. 3Scott JT. Drug-induced gout. Baillieres Clin Rheumatol. 1991;5:39-60. (PMID: 2070427)
17. 1Eastmond CJ, Garton M, Robins S, Riddoch S. The effects of alcoholic beverages on urate metabolism in gout sufferers. Br J Rheumatol. 1995;34:756-9. (PMID: 7551661)
18. 2Faller J, Fox IH. Ethanol-induced hyperuricemia: evidence for increased urate production by activation of adenine nucleotide turnover. N Engl J Med. 1982;307:1598-602. (PMID: 7144847)
19. 2Vandenberg MK, Moxley G, Breitbach SA, Roberts WN. Gout attacks in chronic alcoholics occur at lower serum urate levels than in nonalcoholics. J Rheumatol. 1994;21:700-4. (PMID: 8035396)
20. 1al-Jarallah KF, Shehab DK, Buchanan WW. Rheumatic complications of alcohol abuse. Semin Arthritis Rheum. 1992;22:162-71. (PMID: 1295089)
21. 2Tarng DC, Lin HY, Shyong ML, Wang JS, Yang WC, Huang TP. Renal function in gout patients. Am J Nephrol. 1995;15:31-7. (PMID: 7872362)
22. 2Vuorinen-Markkola H, Yki-Jarvinen H. Hyperuricemia and insulin resistance. J Clin Endocrinol Metab. 1994;78:25-9. (PMID: 8288709)
23. 1Rigby AS, Wood PH. Serum uric acid levels and gout: what does this herald for the population? Clin Exp Rheumatol. 1994;12:395-400. (PMID: 7955603)
24. 2Hasselbacher P. Variation in synovial fluid analysis by hospital laboratories. Arthritis Rheum. 1987;30:637-42. (PMID: 3606682)
25. 2Walker DJ, Young I, Hassey GA, Smith AM, Goring M, Platt PN. The acute hot joint in medical practice. J R Coll Physicians Lond. 1995;29:101-4. (PMID: 7595882)
26. 3Bomalaski JS, Lluberas G, Schumacher HR Jr. Monosodium urate crystals in the knee joints of patients with asymptomatic nontophaceous gout. Arthritis Rheum. 1986;29:1480-4. (PMID: 3801071)
27. 2Pascual E, Batlle-Gualda E, Martínez A, Rosas J, Vela P. Synovial fluid analysis for diagnosis of intercritical gout. Ann Intern Med. 1999;131:756-9. (PMID: 10577299) [Full Text]
28. 3Ropes MM, Bauer W. Synovial fluid changes and joint disease. Cambridge, MA: Harvard University Press; 1953.
29. 3Shmerling RH, Stern SH, Gravallese EM, Kantrowitz FG. Tophaceous deposition in the finger pads without gouty arthritis. Arch Intern Med. 1988;148:1830-2. (PMID: 3401106)
30. 3Wernick R, Winkler C, Campbell S. Tophi as the initial manifestation of gout. Report of six cases and review of the literature. Arch Intern Med. 1992;152:873-6. (PMID: 1558451)
31. 3Nakayama DA, Barthelemy C, Carrera G, Lightfoot RW Jr, Wortmann RL. Tophaceous gout: a clinical and radiographic assessment. Arthritis Rheum. 1984;27:468-71. (PMID: 6712761)
32. 2Yu JS, Chung C, Recht M, Dailiana T, Jurdi R. MR imaging of tophaceous gout. AJR Am J Roentgenol. 1997;168:523-7. (PMID: 9016240)
33. 1Lawrence RC, Helmick CG, Arnett FC, Deyo RA, Felson DT, Giannini EH, et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum. 1998;41:778-99. (PMID: 9588729)
34. 2Wilkins E, Dieppe P, Maddison P, Evison G. Osteoarthritis and articular chondrocalcinosis in the elderly. Ann Rheum Dis. 1983;42:280-4. (PMID: 6859960)
35. 2Wolfe F, Cathey MA. The misdiagnosis of gout and hyperuricemia. J Rheumatol. 1991;18:1232-4. (PMID: 1941830)
36. 2Lyu LC, Hsu CY, Yeh CY, Lee MS, Huang SH, Chen CL. A case-control study of the association of diet and obesity with gout in Taiwan. Am J Clin Nutr. 2003;78:690-701. (PMID: 14522726)
37. 2Choi HK, Atkinson K, Karlson EW, Willett W, Curhan G. Alcohol intake and risk of incident gout in men: a prospective study. Lancet. 2004;363:1277-81. (PMID: 15094272)
38. 1Zöllner N, Griebsch A. Diet and gout. Adv Exp Med Biol. 1974;41:435-42. (PMID: 4832568)
39. 2Choi HK, Atkinson K, Karlson EW, Willett W, Curhan G. Purine-rich foods, dairy and protein intake, and the risk of gout in men. N Engl J Med. 2004;350:1093-103. (PMID: 15014182)
40. 3Choi JW, Ford ES, Gao X, Choi HK. Sugar-sweetened soft drinks, diet soft drinks, and serum uric acid level: the Third National Health and Nutrition Examination Survey. Arthritis Rheum. 2008;59:109-16. (PMID: 18163396)
41. 2Choi HK, Curhan G. Soft drinks, fructose consumption, and the risk of gout in men: prospective cohort study. BMJ. 2008;336:309-12. (PMID: 18244959)
42. 3Rosenthal AK, Ryan LM. Treatment of refractory crystal-associated arthritis. Rheum Dis Clin North Am. 1995;21:151-61. (PMID: 7732165)
43. 1Wallace SL, Singer JZ. Therapy in gout. Rheum Dis Clin North Am. 1988;14:441-57. (PMID: 3051159)
44. 2Alloway JA, Moriarty MJ, Hoogland YT, Nashel DJ. Comparison of triamcinolone acetonide with indomethacin in the treatment of acute gouty arthritis. J Rheumatol. 1993;20:111-3. (PMID: 8441139)
45. 2Axelrod D, Preston S. Comparison of parenteral adrenocorticotropic hormone with oral indomethacin in the treatment of acute gout. Arthritis Rheum. 1988;31:803-5. (PMID: 2454635)
46. 1Ritter J, Kerr LD, Valeriano-Marcet J, Spiera H. ACTH revisited: effective treatment for acute crystal induced synovitis in patients with multiple medical problems. J Rheumatol. 1994;21:696-9. (PMID: 8035395)
47. 3George TM, Mandell BF. Individualizing the treatment of gout. Cleve Clin J Med. 1996;63:150-5. (PMID: 8665653)
48. 2Siegel LB, Alloway JA, Nashel DJ. Comparison of adrenocorticotropic hormone and triamcinolone acetonide in the treatment of acute gouty arthritis. J Rheumatol. 1994;21:1325-7. (PMID: 7966077)
49. 1Groff GD, Franck WA, Raddatz DA. Systemic steroid therapy for acute gout: a clinical trial and review of the literature. Semin Arthritis Rheum. 1990;19:329-36. (PMID: 2196674)
50. 1Janssens HJ, Janssen M, van de Lisdonk EH, van Riel PL, van Weel C. Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial. Lancet. 2008;371:1854-60. (PMID: 18514729)
51. 1Evans TI, Wheeler MT, Small RE, Breitbach SA, Sanders KM, Roberts WN. A comprehensive investigation of inpatient intravenous colchicine use shows more education is needed. J Rheumatol. 1996;23:143-8. (PMID: 8838523)
52. 1Wallace SL, Singer JZ. Review: systemic toxicity associated with the intravenous administration of colchicine—guidelines for use. J Rheumatol. 1988;15:495-9. (PMID: 3288754)
53. 2Loeb JN. The influence of temperature on the solubility of monosodium urate. Arthritis Rheum. 1972;15:189-92. (PMID: 5027604)
54. 1Yamanaka H, Togashi R, Hakoda M, Terai C, Kashiwazaki S, Dan T, et al. Optimal range of serum urate concentrations to minimize risk of gouty attacks during anti-hyperuricemic treatment. Adv Exp Med Biol. 1998;431:13-8. (PMID: 9598023)
55. 2Perez-Ruiz F, Atxotegi J, Hernando I, Calabozo M, Nolla JM. Using serum urate levels to determine the period free of gouty symptoms after withdrawal of long-term urate-lowering therapy: a prospective study. Arthritis Rheum. 2006;55:786-90. (PMID: 17013833)
56. 1Paulus HE, Schlosstein LH, Godfrey RG, Klinenberg JR, Bluestone R. Prophylactic colchicine therapy of intercritical gout. A placebo-controlled study of probenecid-treated patients. Arthritis Rheum. 1974;17:609-14. (PMID: 4606955)
57. 1Borstad GC, Bryant LR, Abel MP, Scroggie DA, Harris MD, Alloway JA. Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis. J Rheumatol. 2004;31:2429-32. (PMID: 15570646)
58. 3Roberts WN, Liang MH, Stern SH. Colchicine in acute gout. Reassessment of risks and benefits. JAMA. 1987;257:1920-2. (PMID: 3820512)
59. 3Lilley LL, Guanci R. ‘Until diarrhea occurs’? There’s a maximum dosage to prevent colchicine toxicity. Am J Nurs. 1999;99:12. (PMID: 10234309)
60. 3Wallace SL, Singer JZ, Duncan GJ, Wigley FM, Kuncl RW. Renal function predicts colchicine toxicity: guidelines for the prophylactic use of colchicine in gout. J Rheumatol. 1991;18:264-9. (PMID: 2023222)
61. 3Dawson TM, Starkebaum G. Colchicine induced rhabdomyolysis. J Rheumatol. 1997;24:2045-6. (PMID: 9330953)
62. 2Cronstein BN, Molad Y, Reibman J, Balakhane E, Levin RI, Weissmann G. Colchicine alters the quantitative and qualitative display of selectins on endothelial cells and neutrophils. J Clin Invest. 1995;96:994-1002. (PMID: 7543498)
63. 2Hung IF, Wu AK, Cheng VC, Tang BS, To KW, Yeung CK, et al. Fatal interaction between clarithromycin and colchicine in patients with renal insufficiency: a retrospective study. Clin Infect Dis. 2005;41:291-300. (PMID: 16007523)
64. 2Fries JF, Williams CA, Bloch DA, Michel BA. Nonsteroidal anti-inflammatory drug-associated gastropathy: incidence and risk factor models. Am J Med. 1991;91:213-22. (PMID: 1892140)
65. 2Vazquez-Mellado J, Morales EM, Pacheco-Tena C, Burgos-Vargas R. Relation between adverse events associated with allopurinol and renal function in patients with gout. Ann Rheum Dis. 2001;60:981-3. (PMID: 11557658)
66. 2Becker MA, Schumacher HR Jr, Wortmann RL, MacDonald PA, Eustace D, Palo WA, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005;353:2450-61. (PMID: 16339094)
67. 1Schumacher HR Jr, Becker MA, Wortmann RL, Macdonald PA, Hunt B, Streit J, et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum. 2008;59:1540-8. (PMID: 18975369)
68. 3Khosravan R, Kukulka MJ, Wu JT, Joseph-Ridge N, Vernillet L. The effect of age and gender on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase. J Clin Pharmacol. 2008;48:1014-24. (PMID: 18635756)
69. 2Schumacher HR Jr, Becker MA, Lloyd E, MacDonald PA, Lademacher C. Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study. Rheumatology (Oxford). 2009;48:188-94. (PMID: 19141576)
70. 3Persellin RH and Schmid FR. The use of sulfinpyrazone in the treatment of gout. JAMA. 1961;175:971-75.
71. 3Emmerson BT. The management of gout. N Engl J Med. 1996;334:445-51. (PMID: 8552148)
72. 3Simkin PA. Gout and hyperuricemia. Curr Opin Rheumatol. 1997;9:268-73. (PMID: 9204265)
73. 3Wise CM, Agudelo CA. Gouty arthritis and uric acid metabolism. Curr Opin Rheumatol. 1996;8:248-54. (PMID: 8796986)
74. 2Puig JG, Miranda ME, Mateos FA, Picazo ML, Jiménez ML, Calvin TS, et al. Hereditary nephropathy associated with hyperuricemia and gout. Arch Intern Med. 1993;153:357-65. (PMID: 8427538)
75. 2Scott JT. Comparison of allopurinol and probenecid. Ann Rheum Dis. 1966;25:623-6. (PMID: 5335059)
76. 3Copeman WSC. A short history of gout. Berkeley, CA: University of California Press; 1964.
77. 1Shrestha M, Morgan DL, Moreden JM, Singh R, Nelson M, Hayes JE. Randomized double-blind comparison of the analgesic efficacy of intramuscular ketorolac and oral indomethacin in the treatment of acute gouty arthritis. Ann Emerg Med. 1995;26:682-6. (PMID: 7492036)
78. 2Shrestha M, Chiu MJ, Martin RL, Cush JJ, Wainscott MS. Treatment of acute gouty arthritis with intramuscular ketorolac tromethamine. Am J Emerg Med. 1994;12:454-5. (PMID: 8031433)
New References of Interest
79. Dehghan A, Köttgen A, Yang Q, Hwang SJ, Kao WL, Rivadeneira F, et al. Association of three genetic loci with uric acid concentration and risk of gout: a genome-wide association study. Lancet. 2008;372:1953-61. (PMID: 18834626)
FAQs
Grace P. Teal, MD (deceased) has no financial relationships with pharmaceutical companies, biomedical device manufacturers, or health-care related organizations. Howard A. Fuchs, MD, is a consultant for TAP Pharmaceuticals.
Steven E. Weinberger, MD, FACP, Acting Editor, PIER, has stock holdings in Glaxosmithkline and Abbott.

The information included herein should never be used as a substitute for clinical judgment and does not represent an official position of ACP. Because all PIER modules are updated regularly, printed web pages or PDFs may rapidly become obsolete. Therefore, PIER users should compare the date of the last update on the website with any printout to ensure that the information being referred to is the most current available.
PIER is copyrighted (c) 2009 by the American College of Physicians,
190 N. Independence Mall West, Philadelphia, PA 19106-1572, USA.